Back to top

vaccines: Archive

Zacks Equity Research

Moderna (MRNA) Posts Upbeat Data on Bivalent COVID Booster Jab

Moderna's (MRNA) bivalent COVID booster candidate creates superior neutralizing antibodies compared to its currently authorized COVID vaccine mRNA-1273's booster dose against all variants of concern.

PFEPositive Net Change VRTXPositive Net Change MRNAPositive Net Change BNTXNegative Net Change

Zacks Equity Research

Pfizer (PFE), BioNTech (BNTX) COVID Booster Effective in Young Kids

A third dose of Pfizer (PFE) and partner BioNTech's (BNTX) COVID-19 vaccine achieves a significant immune response against the Omicron variant in children aged between 5 years and 11 years.

PFEPositive Net Change MRNAPositive Net Change COLLPositive Net Change BNTXNegative Net Change

Zacks Equity Research

Novavax (NVAX) COVID Jab Gets Nod for Use in Switzerland

Novavax's (NVAX) Nuvaxovid is the first protein COVID-19 vaccine authorized for use in Switzerland. The stock price rises following the announcement.

PFEPositive Net Change MRNAPositive Net Change NVAXNegative Net Change BNTXNegative Net Change

Kinjel Shah

EU Agencies Doubtful About Need for 2nd COVID Booster

The European health agencies agreed that the fourth dose of mRNA-based COVID-19 vaccines of Pfizer (PFE)/BioNTech (BNTX) and Moderna (MRNA) may be given to adults 80 years and above.

PFEPositive Net Change MRNAPositive Net Change BNTXNegative Net Change

Zacks Equity Research

Novavax (NVAX) Seeks EU Nod for COVID-19 Vaccine in Kids

Novavax (NVAX) seeks label expansion for its COVID-19 vaccine in adolescents aged 12-17 years in the European Union. Currently, the vaccine is authorized for use in adults.

PFEPositive Net Change MRNAPositive Net Change NVAXNegative Net Change BNTXNegative Net Change

Sweta Jaiswal, FRM

Moderna ETFs Rallying on COVID-19 Vaccine Booster Shot Update

Moderna has been rallying on the latest positive booster shot-related update.

MRNAPositive Net Change IBBPositive Net Change BBHNegative Net Change IDNANegative Net Change

Zacks Equity Research

Novavax's (NVAX) COVID Jab Gets EUA Nod for Kids in India

Novavax's (NVAX) COVID-19 vaccine receives its first authorization for emergency use in adolescents aged 12 years and above in India.

PFEPositive Net Change MRNAPositive Net Change NVAXNegative Net Change BNTXNegative Net Change

Zacks Equity Research

Moderna (MRNA) Up on FDA Filing for Second COVID Booster Jab

Moderna (MRNA) seeks the FDA's authorization for a fourth dose of its COVID vaccine in adults who already got an initial authorized booster dose of the same in the United States.

PFEPositive Net Change VRTXPositive Net Change MRNAPositive Net Change BNTXNegative Net Change